2025年5月10日，首届博鳌医疗健康产业全球合作大会（HICC）在海南博鳌盛大开幕。大会以"共享创新无界，共创生态新机"为主题，吸引了全球政策制定 者、院士专家及医疗健康产业领军企业代表共议国际化发展路径等热门议题。在"医疗健康产业国际化发展高峰论坛"分主题论坛中，瑞慈医疗创始人、董事 南通瑞慈医院作为国内最早一批创办的大型综合性民办医院之一，从筹建初期即聚焦国际化视野，在办院理念、学科规划、服务体系等多维度对标国际先进 医疗机构，并通过持续的国际交往与学术交流提升专业、服务能力，先后与韩国三星医疗院、新加坡国立健保集团、日本大坪会、龟田医疗中心、东京医科 大学附属医院等国际高水平医院结成"姐妹医院"。体检板块引进日本精密体检服务，形成标准化健康管理体系，通过"早检早诊早治"助力国人更长寿。旗下 中高端医疗品牌"瑞慈体检"和高端医疗品牌"幸元会"协同发力，实现规模与口碑双提升，并已形成可复制的标准化、品质化的健康管理服务优势。截至2024 年末，体检业务已拓展至全国29个城市，共计83家门店。 中小型民营医疗企业"走出去"的路径选择 中国民营医院历史较短，大约从2000年前后开始发展，至今约25年。瑞慈作为 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 20% growth compared to the previous year[1]. - Revenue for the year ended December 31, 2024, was RMB 2,924.5 million, a decrease of 2.3% compared to RMB 2,992.7 million for the year ended December 31, 2023[21]. - Gross profit for the year ended December 31, 2024, was RMB 1,167.8 million, down 6.5% from RMB 1,249.5 million for the year ended December 31, 2023[21]. - Profit attributable to owners of the company for the year ended December 31, 2024, was RMB 297.3 million, compared to RMB 363.8 million for the year ended December 31, 2023[21]. - Adjusted EBITDA for the year ended December 31, 2024, was RMB 1,054.1 million, a decline of 1.7% from RMB 1,072.4 million for the year ended December 31, 2023[21]. - The company's net profit for 2024 was RMB 354.7 million, down from RMB 402.0 million in 2023, primarily due to a decline in health check business revenue[69]. - The revenue from the comprehensive hospital business in 2024 was RMB 604.4 million, down 3.7% from RMB 627.7 million in 2023[57]. - The revenue from the health check business in 2024 was RMB 2,358.8 million, a decline of 1.1% from RMB 2,386.0 million in 2023[58]. - The gross profit decreased from RMB 1,249.5 million in 2023 to RMB 1,167.8 million in 2024, with a gross margin of 39.9%[61]. User Engagement and Market Expansion - User data showed a 15% increase in active users, reaching 1.2 million by the end of the reporting period[1]. - The company is expanding its market presence, with plans to open 10 new clinics across China in the next year[1]. - The company plans to implement a new digital marketing strategy aimed at increasing brand awareness and user engagement by 40%[1]. - The company aims to deepen strategic transformation and integrate advanced technologies such as AI and big data into its healthcare services[24]. - The health check sector has launched multi-level health management products focusing on early cancer screening and chronic disease management, supported by a digital platform covering 83 health check institutions across 29 cities in China, with 75 already operational[27]. Strategic Initiatives and Innovations - New product launches included a state-of-the-art health monitoring device, expected to contribute an additional $50 million in revenue[1]. - A strategic acquisition of a local healthcare provider was completed, enhancing the company's service offerings and expected to generate $30 million in annual revenue[1]. - Research and development investments increased by 30%, focusing on innovative healthcare technologies[1]. - The company has developed the Rici Medark platform, integrating AI technology to assist doctors in lesion identification and condition grading, aiming for diagnostic quality control in report generation in the future[27]. - The company is committed to strategic goals despite external challenges, emphasizing innovation-driven service upgrades and talent development to enhance its position as a leader in high-quality medical services[28]. Operational Efficiency and Customer Satisfaction - The company reported a net profit margin of 12%, up from 10% in the previous year, indicating improved operational efficiency[1]. - Customer satisfaction ratings improved to 90%, reflecting the company's commitment to quality service[1]. - The health check-up segment achieved a customer satisfaction rate of 98.80%, an increase of 1.1 percentage points year-on-year[53]. Financial Position and Liabilities - The total assets as of December 31, 2024, amounted to RMB 4,858.5 million, an increase from RMB 4,637.8 million as of December 31, 2023[22]. - The total liabilities as of December 31, 2024, were RMB 3,483.4 million, down from RMB 3,523.7 million as of December 31, 2023[22]. - As of December 31, 2024, the company's current liabilities exceeded its current assets by RMB 323.3 million, a decrease from RMB 726.6 million as of December 31, 2023, primarily due to improved collection efficiency of operating receivables[76]. - The company's cash and cash equivalents amounted to RMB 1,109.8 million as of December 31, 2024, up from RMB 811.2 million as of December 31, 2023[77]. - Total bank and other borrowings were RMB 797.0 million as of December 31, 2024, down from RMB 866.6 million as of December 31, 2023[80]. Governance and Board Composition - The board consists of 4 executive directors (57.1%) and 3 independent non-executive directors (42.9%) as of December 31, 2024[99]. - The gender composition of the board is 4 males (57.1%) and 3 females (42.9%)[99]. - The company has a policy ensuring that the gender ratio in the board, senior management, and employees is at least 10%[99]. - All directors participated in continuous professional development activities to enhance their knowledge and skills[102]. - The company has adopted a standard code of conduct for securities trading, with all directors confirming compliance for the year ending December 31, 2024[110]. Risk Management and Compliance - The company has established a comprehensive risk management and internal control framework to actively manage risks[142]. - The main risks identified include business expansion risks, competition risks, and investment risks, with specific measures in place to mitigate these risks[143][145]. - The company emphasizes the importance of anti-fraud measures and has implemented a whistleblower system to encourage reporting of fraudulent activities[159]. - The internal control system is based on COSO principles and has undergone independent audits to ensure effectiveness[160]. - The company is enhancing its compliance system by regularly reviewing legal regulations and industry standards[155]. Environmental, Social, and Governance (ESG) Initiatives - The environmental, social, and governance (ESG) report covers the performance and measures of the company and its 108 subsidiaries for the period from January 1, 2024, to December 31, 2024[173]. - The board of directors commits to strict compliance with listing rules and ESG reporting guidelines, ensuring the accuracy and completeness of the report's content[176]. - The company has published its ESG report for nine consecutive years since 2016, enhancing its internal sustainability system and optimizing ESG management processes[178]. - The company has not faced any fines or lawsuits due to environmental violations during the reporting period, demonstrating compliance with environmental laws[187]. - In 2024, the company aims to continue its efforts in environmental protection and pollution prevention, revising management methods to reduce resource consumption and enhance recycling rates[187].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 RICI HEALTHCARE HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） （股份代號：1526） 截至2024年12月31日止年度年度業績公告 財務概要 於本公告內，凡提及「我們」、及「瑞慈」，均指本公司（定義見下文），倘文義另 有規定，則指本集團（定義見下文）。 瑞慈醫療服務控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然公佈 本公司及其附屬公司（統稱「本集團」）截至2024年12月31日止年度（「報告期間」） 綜合年度業績，連同截至2023年12月31日止年度之比較數字如下： – 1 – ‧ 截至2024年12月31日止年度的收入為人民幣2,924.5百萬元，較截至2023 年12月31日止年度的收入人民幣2,992.7百萬元下降2.3%。 ‧ 截至2024年12月31日止年度的毛利為人民幣1,167.8百萬元，較截至2023 年12月31日止年度的毛利人民幣 ...

RICI HEALTHCARE HOLDINGS LIMITED 瑞慈醫療服務控股 有限公司 2024 INTERIM REPORT 中 期 報 告 目錄 釋義2 公司資料4 管理層討論與分析6 補充資料 16 中期財務資料審閱報告 26 中期簡明綜合財務報表 中期簡明綜合資產負債表 27 中期簡明綜合損益表 29 中期簡明綜合其他全面收益表 30 中期簡明綜合權益變動表 31 中期簡明綜合現金流量表 32 中期簡明綜合財務資料附註 33 釋義 2 | --- | --- | --- | |------------------------------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 1,231.2 million, a decrease of 4.1% compared to RMB 1,284.3 million for the same period in 2023[1] - Gross profit for the same period was RMB 396.3 million, down from RMB 484.0 million in 2023[1] - Profit attributable to owners of the company was RMB 85.0 million, compared to RMB 123.4 million in the prior year[1] - Operating profit for the six months was RMB 185.7 million, down from RMB 228.5 million in the same period last year[6] - Total comprehensive income for the period was RMB 87.7 million, down from RMB 129.9 million in the previous year[7] - The group reported a net profit of RMB 87,121,000 for the period, after tax expenses of RMB 38,027,000[19] - The company reported a net profit of RMB 126,219,000 for the same period, after tax expenses of RMB 53,718,000[21] - Net profit for the period was RMB 87.1 million, down from RMB 126.2 million in the same period of 2023[60] Dividends - The board declared an interim dividend of HKD 0.045 per share for the reporting period[1] - The company declared an interim dividend of HKD 0.045 per share, totaling HKD 71.6 million, to be paid on or around September 23, 2024[78] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 4,542.8 million, a decrease from RMB 4,637.8 million as of December 31, 2023[3] - Total liabilities decreased to RMB 3,356.2 million from RMB 3,523.7 million at the end of 2023[5] - As of June 30, 2024, total assets of the group amounted to RMB 4,542,815,000, while total liabilities were RMB 3,356,183,000[20] - The company’s current liabilities exceeded current assets by RMB 708,191,000 as of June 30, 2024[10] - The total trade payables as of June 30, 2024, were RMB 162,086 thousand, a slight decrease from RMB 164,351 thousand as of December 31, 2023[34] Cash Flow and Financing - The company reported a net cash position of RMB 587.1 million as of June 30, 2024, compared to RMB 811.2 million at the end of 2023[3] - The group’s operating cash flow is primarily supported by cash generated from operations, bank borrowings, and unused bank financing[10] - The company’s bank borrowings stood at RMB 813,500,000 as of June 30, 2024, compared to RMB 850,000,000 as of December 31, 2023[30] - The total bank and other borrowings as of June 30, 2024, were RMB 813.5 million, down from RMB 866.6 million as of December 31, 2023[67] - The group reported financing costs of RMB 60,966 thousand for the six months ended June 30, 2024, compared to RMB 49,039 thousand in 2023, reflecting an increase of 24%[39] Operational Highlights - The comprehensive hospital segment generated revenue of RMB 323,966,000 and a segment profit of RMB 72,356,000[19] - The health check center segment reported revenue of RMB 922,936,000 and a segment profit of RMB 215,616,000[19] - The revenue from the comprehensive hospital business was RMB 308.3 million, an increase of 2.1% from RMB 301.8 million in the same period of 2023[49] - The revenue from the health check business was RMB 922.9 million, a decrease of 6.1% from RMB 982.5 million in the same period of 2023[50] - The group added property, plant, and equipment, right-of-use assets, and intangible assets totaling RMB 321,778,000 during the period[20] Employee and Administrative Expenses - Employee benefit expenses for the first half of 2024 were RMB 501,699 thousand, an increase of 1.3% from RMB 496,103 thousand in the same period last year[38] - The group incurred administrative expenses of RMB 111,793,000 for the six months ended June 30, 2024[19] Market and Industry Insights - In 2023, the total number of medical visits in China reached 6.41 billion, a year-on-year increase of 9.4%[45] - The hospital industry saw 3.86 billion visits, with public hospitals accounting for 3.23 billion visits (up 6.7%) and private hospitals 640 million visits (up 9.3%) from the previous year[45] - The health check-up industry in China grew from 151.1 billion yuan in 2018 to 217 billion yuan in 2022, with a compound annual growth rate of approximately 9.46%[45] Corporate Governance - The company has not separated the roles of Chairman and CEO, with Dr. Fang Yixin holding both positions to facilitate the implementation of new business strategies[80] - The board consists of four executive directors and three independent non-executive directors, ensuring a strong element of independence[80] - The company has adopted the standard code of conduct for securities trading, confirming compliance by all directors during the reporting period[81] Auditor and Reporting - The external auditor, Hong Kong Lixin Dehao CPA Limited, conducted an independent review of the group's interim financial information during the reporting period[83] - The interim report will be published on the Hong Kong Stock Exchange and the company's website, containing all required information[83]

2023年報 股份代號 Stock Code: 1526 於開曼群島註冊成立之有限公司 Incorporated in the Cayman Islands with limited liability 2023 年報 目錄 | 釋義 | 2 | | --- | --- | | 公司資料 | 6 | | 里程碑 | 8 | | 財務概要 | 9 | | 財務摘要 | 10 | | 主席報告 | 11 | | 董事及高級管理層履歷 | 13 | | 管理層討論與分析 | 17 | | 企業管治報告 | 28 | | 環境、社會及管治報告 | 53 | | 董事報告 | 92 | | 獨立核數師報告 | 109 | | 財務報表及財務報表附註 | 114 | 釋義 於本年度報告，除文義另有所指外，否則下列詞彙具有以下涵義。 2 瑞慈醫療服務控股有限公司 「2024年股東週年大會」 指 將於2024年6月19日舉行之股東週年大會 「股東週年大會」 指 本公司股東週年大會 「組織章程細則」或「細則」 指 不時修訂的本公司組織章程大綱及細則 「審核委員會」 指 董事會審核委員會 「北京瑞慈」 指 北京瑞慈瑞泰綜合門診部 ...

Financial Performance - For the year ended December 31, 2023, the revenue from continuing operations was RMB 2,992.7 million, an increase of 26.0% compared to RMB 2,375.0 million for the year ended December 31, 2022[1]. - The gross profit from continuing operations for the year ended December 31, 2023, was RMB 1,249.5 million, reflecting a 34.8% increase from RMB 927.2 million for the year ended December 31, 2022[1]. - The profit attributable to owners of the company for the year ended December 31, 2023, was RMB 363.8 million, up 25.1% from RMB 290.8 million for the year ended December 31, 2022[1]. - The adjusted EBITDA from continuing operations for the year ended December 31, 2023, was RMB 1,072.4 million, representing a 30.9% increase from RMB 819.1 million for the year ended December 31, 2022[1]. - The operating profit for the year ended December 31, 2023, was RMB 656.9 million, compared to RMB 431.7 million for the year ended December 31, 2022[20]. - The net profit from continuing operations for the year ended December 31, 2023, was RMB 401.975 million, up from RMB 243.149 million for the year ended December 31, 2022[20]. - The company's net profit for the year ended December 31, 2023, was RMB 401,975 thousand, representing a 50.4% increase from RMB 267,187 thousand in 2022[25]. - Total comprehensive income for the year was RMB 402,350 thousand, up from RMB 268,912 thousand in the previous year, marking a growth of 49.5%[25]. Revenue Breakdown - Total revenue for the year ended December 31, 2023, was RMB 2,992,689,000, with a segment profit of RMB 868,925,000[60]. - The comprehensive hospital segment generated revenue of RMB 627,659,000, while the health check center segment contributed RMB 2,386,006,000[60]. - The health check-up business revenue reached RMB 2,386.0 million in 2023, a 35.2% increase from RMB 1,765.4 million in 2022, driven by a 31.8% growth in the number of check-ups and a 2.6% increase in average spending per person[137]. - Outpatient service revenue was RMB 84,198 thousand, down 4.3% from RMB 88,122 thousand in 2022[100]. - Inpatient service revenue increased to RMB 256,107 thousand, up 11.3% from RMB 230,269 thousand in 2022[100]. Assets and Liabilities - As of December 31, 2023, total assets amounted to RMB 4,637,755,000, with total liabilities of RMB 3,523,710,000[60]. - The company's equity attributable to owners increased to RMB 1,114,045 thousand from RMB 904,826 thousand, marking a growth of 23.1%[44]. - The total liabilities decreased to RMB 3,523,710 thousand from RMB 3,662,032 thousand, indicating a reduction of 3.8%[44]. - The financial liabilities of the group were RMB 3,269.1 million, a decrease from RMB 3,426.6 million as of December 31, 2022[8]. - Total assets as of December 31, 2023, amounted to RMB 4,637,755 thousand, a slight increase from RMB 4,566,858 thousand in 2022[34]. Employee and Operational Metrics - The number of employees in the group as of December 31, 2023, was 9,413, an increase from 8,737 as of December 31, 2022[16]. - The group operated 79 health check-up centers nationwide as of December 31, 2023, with 72 centers already in operation, covering 29 cities[158]. - The number of outpatient visits in the first nine months of 2023 reached 5.11 billion, a year-on-year increase of 6%[107]. - The nursing home operated at an occupancy rate of 89.6% as of December 31, 2023, down from 94.2% in 2022[110]. Cost and Expenses - The income tax expense for continuing operations in 2023 was RMB 143.7 million, compared to RMB 84.0 million in 2022, primarily due to the increase in profit from continuing operations[12]. - The group reported administrative expenses of RMB 223,845,000 and net impairment losses on financial assets of RMB 9,042,000[60]. - Employee benefit expenses increased to RMB 1,098,021, up from RMB 901,209 in 2022, reflecting a growth of approximately 21.8%[121]. - The sales cost for the health check business rose by 29.0% to RMB 1,260.5 million in 2023, driven by an increase in the number of health check visits[166]. Strategic Initiatives - The company established a Shanghai medical service center, enhancing its market expansion efforts by connecting with over 150 top doctors from 20 hospitals[129]. - The company’s collaboration with Fudan University hospitals focuses on oncology, indicating a strategic move towards specialized medical services[130]. - The group plans to continue focusing on high-end health check-up services and expand its presence in key markets such as Shanghai, Beijing, Jiangsu, the Greater Bay Area, and Zhejiang[158]. - The company implemented a "patient satisfaction first" action plan to enhance patient experience and satisfaction[163]. - The company aims to establish itself as one of the three major medical centers in Nantong by creating a comprehensive hospital with a focus on high-quality specialty development[163]. Dividends and Shareholder Returns - The group declared a special dividend of HKD 0.13 per share, totaling HKD 206,742,000 (approximately RMB 187,904,000)[153]. - Basic and diluted earnings per share attributable to owners of the company from continuing operations for the year ended December 31, 2023, was RMB 0.23, compared to RMB 0.18 for the year ended December 31, 2022[23]. - Basic and diluted earnings per share increased to RMB 0.23 from RMB 0.15, indicating a growth of 53.3%[31].

智通财经APP讯，瑞慈医疗(01526)发布公告，预期公司截至2023年12月31日止年度取得的公司拥有人应占溢利不超过人民币3.9亿元及不少于人民币3.5亿元。而截至2022年12月31日止年度的公司拥有人应占溢利为人民币2.91亿元。 公告称，预期取得截至2023年12月31日止年度的公司拥有人应占溢利主要由于2023年公司体检业务强劲复苏并实现进一步增长，全年收入大幅提升。 ...

2023 INTERIM REPORT 中 期 報 告 | --- | --- | |----------------------------|-------| | 釋義 | 2 | | 公司資料 | 4 | | 管理層討論與分析 | 6 | | 補充資料 | 16 | | 中期財務資料審閱報告 | 25 | | 中期簡明綜合財務報表 | | | 中期簡明綜合資產負債表 | 27 | | 中期簡明綜合損益表 | 29 | | 中期簡明綜合其他全面收益表 | 30 | | 中期簡明綜合權益變動表 | 31 | | 中期簡明綜合現金流量表 | 32 | | 中期簡明綜合財務資料附註 | 33 | RICI HEALTHCARE HOLDINGS LIMITED 瑞慈醫療服務控股 有限公司 目錄 | --- | --- | --- | |------------------------------------------------------------------|-------|------------------------------------------------------------------ ...

截至2023年6月30日止六個月（未經審核） 於2023年6月30日 截至2023年6月30日止 物業及設備、使用權資產 – 14 – 物業 設備 土地使用權 總計 人民幣千元 人民幣千元 人民幣千元 人民幣千元 7 貿易應收款項 | --- | --- | --- | |-----------------------------|--------------------|-----------------| | | 未經審核 | 經審核 | | | 於 2023 年 | 於 2022 年 | | | 6 月 30 日 | 12 月 31 日 | | | 人民幣千元 | 人民幣千元 | | 貿易應收款項 減：虧損撥備 | 256,360 (10,946) | 287,752 (9,040) | | | 245,414 | 278,712 | 於2023年6月30日及2022年12月31日，本集團貿易應收款項公平值與其賬面 值相若。 基於相關服務提供日期的貿易應收款項賬齡分析如下： – 17 – 於2022年12月31日，固定存款人民幣63,500,000元尚未被銀行系統解 禁，並已於2023年1月6日解禁。 ...